[EN] HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'AMIDES HÉTÉROCYCLIQUES UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR P2X7
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2014115072A1
公开(公告)日:2014-07-31
The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.
[EN] TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE TÉTRAHYDROQUINOLÉINE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7
申请人:RAQUALIA PHARMA INC
公开号:WO2018168818A1
公开(公告)日:2018-09-20
The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.
[EN] HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'AMIDE HÉTÉROCYCLIQUE COMME ANTAGONISTES DU RÉCEPTEUR P2X7
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2013108227A1
公开(公告)日:2013-07-25
The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, X and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.
Heterocyclic amide derivatives as P2X7 receptor antagonists
申请人:ACTELION PHARMACEUTICALS LTD
公开号:US09388197B2
公开(公告)日:2016-07-12
The invention relates to heterocyclic amide derivatives of formula (I),
wherein R1, R2, R3, R4, R5, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.
Tetrahydroquinoline derivatives as P2X7 receptor antagonists
申请人:RaQualia Pharma Inc.
公开号:US11077100B2
公开(公告)日:2021-08-03
The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.